Agree in terms of the FDA approval in NOV can be positive or negative, however SP was above 4.50 regardless of the FDA approval or not. It's the 2nd largest company in it's field. Market over reacted on the FDA postponed - more evidence requested - approval.
As it has happened before a few months ago. IMO SP should be above 4 regardless of the approval. With the potential approval in NOV the price should be above 6-7 based on the company fundaments.
